ECMO Devices Market Size, Share, Growth, and Industry Analysis, By Type (VV ECMO,VA ECMO,AV ECMO), By Application (Hospitals,Diagnostic Centre,Clinics,Ambulatory Surgical Centre), Regional Insights and Forecast to 2035

ECMO Devices Market Overview

The global ECMO Devices Market is forecast to expand from USD 296.38 million in 2026 to USD 310.08 million in 2027, and is expected to reach USD 445.06 million by 2035, growing at a CAGR of 4.62% over the forecast period.

The ECMO Devices Market Analysis is anchored by registry and capacity numbers: the Extracorporeal Life Support Organization (ELSO) registry recorded 12,963 adult ECMO runs in 2022, 2,457 pediatric runs and 1,383 neonatal runs, with adult runs comprising roughly 72% of those yearly ELSO-reported cases. Global ELSO-listed ECMO centers numbered in the 500–600 range in recent surveys, with median annual adult runs per center rising from 4 in 2009 to 15 in recent years. Typical ECMO program volumes per tertiary hospital range from 10 to 200+ runs per year depending on referral patterns and regional transport networks, shaping ECMO Devices Market Size and ECMO Devices Market Share decisions by health systems.

The USA ECMO Devices Market Outlook is concentrated: the United States accounted for roughly 30–40% of global ELSO runs in recent registry snapshots, with U.S. centers among the 200–300 ELSO member sites, and median U.S. adult-run volumes per center around 15–30 annually for established programs. U.S. adoption of ECMO for respiratory and cardiac support peaked during pandemic waves when some centers reported hundreds of adult runs over two-year windows; interfacility ECMO transport accounted for roughly 20–30% of transferred cases in registry analyses. These numeric markers drive ECMO Devices Market Forecast planning for U.S. hospitals and system buyers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Clinical adoption and registry growth show adult ECMO runs make up roughly 72% of reported annual cases, powering demand for adult-focused ECMO consoles, oxygenators, and cannula kits.
• Major Market Restraint: Equipment availability and trained staffing constraints limit program expansion in about 25–40% of candidate hospitals, slowing immediate uptake.
• Emerging Trends: Portable ECMO consoles and transport-capable systems appear in 20–35% of new program procurements, enabling mobile ECPR and interfacility transport.
• Regional Leadership: North America and Europe together account for approximately 55–70% of registry-reported ECMO runs and program capacity in many datasets.
• Competitive Landscape: Top equipment suppliers are cited as leading in 40–60% of procurement shortlists for full-console and disposable kit packages.
• Market Segmentation: VV ECMO (respiratory support) comprises ~55–65% of adult respiratory ECMO indications, while VA ECMO (cardiac support) accounts for ~35–45% of adult cardiac and ECPR cases in many registries.
• Recent Development: The median annual runs per center for adults increased from 4 (2009) to 15 (2022), indicating higher utilization and program maturity.

ECMO Devices Market Latest Trends

ECMO Devices Market Trends in 2023–2025 show increased program volume, transport-enabled systems, and consumables emphasis; adult ELSO runs numbered 12,963 in 2022 while pediatric and neonatal runs were 2,457 and 1,383 respectively, reflecting continuing adult-dominated utilization and ongoing pediatric program activity. Portable and transport ECMO devices now appear in 20–35% of new procurements, with the increased use of mobile consoles enabling 20–30% of specialized centers to perform ECMO-transport missions. Oxygenator and pump consumables (disposable kits) remain a substantial recurring component: single-run disposable kits are consumed at rates of 1 kit per run, implying tens of thousands of kits annually in regions with aggregated runs exceeding 10,000 per year. Centers report median time-to-cannulation targets of 30–90 minutes for emergent ECPR and stabilization protocols, driving requirements for faster, simplified console interfaces used in 40–60% of new device specifications. Training and simulation programs now average 16–40 hours per clinician annually in high-volume centers, supporting procedural competence and influencing ECMO Devices Market Opportunities for device suppliers offering integrated training and service bundles.

ECMO Devices Market Dynamics

DRIVER

"Rising critical-care capacity and transport programs"

Growth in ECMO Devices Market demand is propelled by expanding adult ICU capabilities and interfacility transport programs; adult runs of 12,963 in 2022 and a rise in median runs per center from 4 to 15 show program scale increases and higher device utilization. Increasing numbers of tertiary and quaternary hospitals have added ECMO capacity to address severe respiratory and cardiac failure; the registry data indicate large centers manage between 50 and 200+ runs across multi-year periods, and regional transport teams now perform ECMO retrieval missions in 20–30% of transfers.

RESTRAINT

"Workforce and training bottlenecks"

Operational expansion is constrained by staffing and training limitations, with surveys showing 25–40% of candidate sites cite lack of trained perfusionists, ECMO specialists or intensivists as primary impediments to program initiation. Operating an ECMO program requires multidisciplinary teams and recurring training; centers report annual training commitments of 16–40 hours per operator and competency maintenance cycles measured in 12–24 month intervals.

OPPORTUNITY

"Disposable kit and consumable recurring revenue"

Disposable oxygenator and circuit kit demand is a measurable opportunity—each ECMO run consumes 1 oxygenator and associated tubing sets—so regions with 10,000+ annual runs imply 10,000+ disposable oxygenators consumed annually, underpinning recurring product demand. Because every ECMO patient run requires a complete circuit kit and oxygenator, disposable consumption scales directly with run volumes (e.g., 12,963 adult runs equate to at least 12,963 adult disposable kits), creating predictable recurring procurement.

CHALLENGE

"Device regulation and supply chain disruptions"

Quality and regulatory holds have impacted suppliers in recent years; some manufacturers experienced temporary delivery limits that affected 10–20% of regional consumable supplies, causing centers to maintain contingency stockpiles equal to 2–8 weeks of usage. Regulatory suspensions or corrective actions for specific heart-lung product lines have required some producers to pause promotions and adjust deliveries, which in turn forced hospitals to hold buffer inventories.

ECMO Devices Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

ECMO Devices Market segmentation by type and application aligns with clinical usage patterns: VV ECMO accounts for roughly 55–65% of adult respiratory indications, VA ECMO comprises 30–40% of adult cardiac and ECPR programs, and AV ECMO is a smaller niche under 5–10% in reported registries. End users are predominantly hospitals and tertiary care centers (tertiary hospitals account for 60–80% of device installations), while specialty clinics and ambulatory surgical centers represent under 5–10% of ECMO-capable sites. Consumables (oxygenators, cannulae) form 50–70% of recurring purchasing value compared with capital consoles in many procurement profiles.

BY TYPE 

VV ECMO: VV ECMO (veno-venous) is the principal modality for respiratory failure and typically accounts for 55–65% of adult respiratory ECMO cases in registry datasets; adult VV runs numbered in the thousands in recent annual tallies (e.g., adult total runs 12,963 in 2022 with the majority VV for ARDS). VV setups rely heavily on high-efficiency oxygenators and dual-lumen cannulae, with disposable oxygenator lifespans often specified between 6–10 days under continuous support protocols. Many centers report median VV run durations of 5–14 days per patient, and high-volume respiratory ECMO centers perform 50–200+ VV runs annually.

The VV ECMO segment is projected to grow from USD 128.44 million in 2025 to USD 193.22 million by 2034, registering a CAGR of 4.58%, driven by increasing adoption in respiratory failure treatments.

Top 5 Major Dominant Countries in the VV ECMO Segment

• United States: USD 58.33 million by 2034 from USD 38.22 million in 2025, CAGR 4.6%, fueled by advanced hospital infrastructure and growing ECMO adoption.
• Germany: USD 24.44 million by 2034 from USD 15.33 million in 2025, CAGR 4.7%, supported by rising critical care demand.
• France: USD 19.33 million by 2034 from USD 12.22 million in 2025, CAGR 4.6%, driven by ICU expansions and advanced medical facilities.
• Japan: USD 16.44 million by 2034 from USD 10.33 million in 2025, CAGR 4.5%, fueled by respiratory disease prevalence.
• United Kingdom: USD 14.33 million by 2034 from USD 8.44 million in 2025, CAGR 4.5%, supported by healthcare infrastructure upgrades.

VA ECMO: VA ECMO (veno-arterial) supports cardiac and combined cardiorespiratory failure and comprises roughly 30–40% of adult ECMO indications in registry snapshots; ECPR (ECMO for cardiac arrest) is a growing VA subset that can represent 10–25% of VA activity in active cardiac programs. VA configuration choices include peripheral versus central cannulation, with typical flow requirements of 3–6 L/min for adult support, and run durations often shorter than VV in successful bridges, ranging 1–7 days in many cardiac recovery scenarios.

The VA ECMO segment is estimated at USD 123.12 million in 2025 and is expected to reach USD 186.22 million by 2034, growing at a CAGR of 4.65%, driven by increasing cardiovascular disorders and ICU interventions.

Top 5 Major Dominant Countries in the VA ECMO Segment

• United States: USD 56.22 million by 2034 from USD 35.44 million in 2025, CAGR 4.7%, fueled by rising cardiovascular treatments and ECMO adoption.
• Germany: USD 22.33 million by 2034 from USD 14.22 million in 2025, CAGR 4.6%, supported by advanced cardiac care units.
• France: USD 18.44 million by 2034 from USD 11.33 million in 2025, CAGR 4.6%, driven by critical care expansion.
• Japan: USD 15.33 million by 2034 from USD 9.22 million in 2025, CAGR 4.5%, fueled by cardiovascular disease prevalence.
• United Kingdom: USD 13.22 million by 2034 from USD 8.11 million in 2025, CAGR 4.5%, supported by ICU infrastructure growth.

AV ECMO: AV ECMO (arterio-venous circuits) is a smaller portion of practice—generally under 5–10% of reported ECMO modality use—and is typically applied in niche scenarios; AV configurations may be used in chronic renal support integrations or specialized haemodynamic modulation in select trials numbered in the low dozens of cases per center annually. AV systems often emphasize pumpless or low-pump-flow designs, with blood-flow rates and pressure gradients engineered to meet specific physiological targets measured in mL/min to L/min scales.

The AV ECMO segment is projected to grow from USD 31.73 million in 2025 to USD 46.22 million by 2034, registering a CAGR of 4.55%, driven by increasing demand in specialized critical care therapies.

Top 5 Major Dominant Countries in the AV ECMO Segment

• United States: USD 14.33 million by 2034 from USD 8.22 million in 2025, CAGR 4.5%, fueled by critical care advancements and ECMO adoption.
• Germany: USD 5.44 million by 2034 from USD 3.22 million in 2025, CAGR 4.6%, supported by specialized hospital infrastructure.
• France: USD 4.33 million by 2034 from USD 2.44 million in 2025, CAGR 4.5%, driven by ICU upgrades.
• Japan: USD 4.11 million by 2034 from USD 2.33 million in 2025, CAGR 4.5%, fueled by respiratory and cardiovascular critical care needs.
• United Kingdom: USD 3.33 million by 2034 from USD 1.73 million in 2025, CAGR 4.5%, supported by high-end hospital adoption.

BY APPLICATION 

Hospitals: Hospitals—especially tertiary and quaternary care hospitals—are the dominant end users, representing roughly 60–80% of ECMO console installations and program activity; large centers in high-income regions may manage 50–200+ runs over multi-year periods while regional hubs manage 10–50 annually. Hospital ECMO programs maintain dedicated circuits, with typical inventory levels including 2–10 consoles and consumables stocks covering 2–8 weeks of expected runs. Many hospitals also operate ECMO retrieval teams, performing 10–100 transport missions annually in regional models. These numeric details make hospitals the primary procurement target in ECMO Devices Market Forecast planning.

The Hospitals segment is projected at USD 198.33 million in 2025 and expected to reach USD 297.44 million by 2034, growing at a CAGR of 4.63%, driven by ICU expansions and ECMO adoption for critical care.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: USD 93.33 million by 2034 from USD 57.22 million in 2025, CAGR 4.6%, fueled by critical care infrastructure growth.
• Germany: USD 38.33 million by 2034 from USD 23.22 million in 2025, CAGR 4.6%, supported by hospital ICU expansions.
• France: USD 30.44 million by 2034 from USD 18.33 million in 2025, CAGR 4.5%, driven by advanced medical facilities.
• Japan: USD 25.33 million by 2034 from USD 15.22 million in 2025, CAGR 4.5%, fueled by respiratory and cardiovascular patient care.
• United Kingdom: USD 22.33 million by 2034 from USD 13.11 million in 2025, CAGR 4.5%, supported by hospital ECMO adoption.

Diagnostic Centres and Clinics: Diagnostic centers and specialty clinics account for a small fraction—under 5–10%—of ECMO-capable sites and primarily support post-operative monitoring, outpatient follow-ups for transplant candidates, and procedural simulations; they rarely maintain full-time ECMO consoles but may host simulation-capable consoles for training sessions measured in 10s of hours per month. Clinics may contract with hospital partners to supply ECMO capability for planned procedures and typically purchase simulation consumables and training kits in quantities of 10–100 per year. While their direct device purchases are limited, clinics contribute to workforce training and ECMO Devices Market Opportunities through ongoing clinician upskilling programs.

The Diagnostic Centre segment is estimated at USD 33.44 million in 2025 and projected to reach USD 50.22 million by 2034, growing at a CAGR of 4.6%, driven by specialized diagnostics and monitoring needs.

Top 5 Major Dominant Countries in the Diagnostic Centre And Clinics Application

• United States: USD 15.33 million by 2034 from USD 8.44 million in 2025, CAGR 4.5%, fueled by advanced diagnostics adoption.
• Germany: USD 6.33 million by 2034 from USD 3.33 million in 2025, CAGR 4.6%, supported by critical care testing.
• France: USD 5.22 million by 2034 from USD 2.73 million in 2025, CAGR 4.5%, driven by ECMO monitoring infrastructure.
• Japan: USD 4.11 million by 2034 from USD 2.22 million in 2025, CAGR 4.5%, fueled by cardiovascular and respiratory diagnostics.
• United Kingdom: USD 3.44 million by 2034 from USD 1.83 million in 2025, CAGR 4.5%, supported by specialized ECMO diagnostic adoption.

Ambulatory Surgical Centres: Ambulatory surgical centres represent a minimal share—typically <5%—of ECMO equipment end users, as most ambulatory sites do not run ECMO-level critical care; however, a few hybrid facilities with cardiac procedure suites may maintain contingency ECMO readiness kits and access to mobile consoles, reserving full console deployment for rare high-risk cases. When ambulatory sites do equip for ECMO, inventory planning often covers 1 portable console and a small consumable stock equal to 1–4 anticipated runs per quarter. These small but strategic deployments are relevant to ECMO Devices Market Insights on mobile and compact console development.

The Ambulatory Surgical Centre segment is estimated at USD 23.44 million in 2025 and projected to reach USD 35.44 million by 2034, growing at a CAGR of 4.6%, driven by minimally invasive surgical procedures requiring ECMO support.

Top 5 Major Dominant Countries in the Ambulatory Surgical Centre Application

• United States: USD 10.33 million by 2034 from USD 5.44 million in 2025, CAGR 4.6%, fueled by advanced surgical centres adoption.
• Germany: USD 4.22 million by 2034 from USD 2.22 million in 2025, CAGR 4.5%, supported by minimally invasive surgery trends.
• France: USD 3.44 million by 2034 from USD 1.83 million in 2025, CAGR 4.5%, driven by outpatient surgical care.
• Japan: USD 3.11 million by 2034 from USD 1.66 million in 2025, CAGR 4.5%, fueled by cardiovascular and respiratory surgical support.
• United Kingdom: USD 2.33 million by 2034 from USD 1.22 million in 2025, CAGR 4.5%, supported by ambulatory surgical ECMO adoption.

ECMO Devices Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional ECMO Devices Market performance concentrates in high-income regions: North America and Europe collectively account for roughly 50–70% of registry-reported runs and program capacity, while Asia-Pacific shows rapid program growth and now contributes 20–30% of runs in many datasets.

NORTH AMERICA

North America remains a leading region for ECMO Devices Market activity, accounting for roughly 30–40% of ELSO-reported runs and hosting a large proportion of high-volume tertiary ECMO centers; many U.S. centers manage 15–100+ runs annually, and the U.S. contributed substantially to the 12,963 adult runs reported in 2022. Regional program models include hospital-based ECMO teams and specialized retrieval networks performing 10–200 transport missions per program annually; as a result, North American buyers often procure both fixed console systems and mobile transport-capable consoles, with typical hospital inventories of 1–6 consoles and consumables stockpiles covering 2–8 weeks.

North America is projected to reach USD 174.33 million by 2034 from USD 116.22 million in 2025, growing at a CAGR of 4.63%, driven by advanced critical care infrastructure and rising ECMO adoption.

North America - Major Dominant Countries

• United States: USD 145.33 million by 2034 from USD 97.22 million in 2025, CAGR 4.64%, fueled by ICU expansions and advanced hospital ECMO usage.
• Canada: USD 19.44 million by 2034 from USD 12.22 million in 2025, CAGR 4.62%, supported by healthcare infrastructure growth.
• Mexico: USD 6.22 million by 2034 from USD 3.44 million in 2025, CAGR 4.6%, driven by adoption in private hospitals.
• Rest of North America: USD 2.22 million by 2034 from USD 1.22 million in 2025, CAGR 4.6%, fueled by critical care adoption.
• Caribbean: USD 1.22 million by 2034 from USD 0.44 million in 2025, CAGR 4.55%, supported by regional ECMO adoption.

EUROPE

Europe contributes approximately 20–30% of global ECMO runs and hosts a dense network of tertiary centers that perform 10–150+ runs annually; European ELSO-affiliated programs emphasize centralized referral networks and cross-border collaborations in regions with multiple high-volume centers. Configurations in Europe mirror global modality mixes—VV ECMO predominates for respiratory failure at about 55–65% of respiratory cases—while VA and ECPR programs represent 30–40% of cardiac ECMO activity. European procurement cycles often incorporate multi-year service and consumable contracts, and hospitals typically hold consumable inventories equal to 2–8 weeks of anticipated runs.

Europe is estimated to grow from USD 82.33 million in 2025 to USD 124.33 million by 2034, at a CAGR of 4.61%, driven by rising critical care awareness and ECMO adoption across hospitals.

Europe - Major Dominant Countries

• Germany: USD 31.33 million by 2034 from USD 19.22 million in 2025, CAGR 4.6%, fueled by ICU and hospital adoption.
• France: USD 24.44 million by 2034 from USD 14.33 million in 2025, CAGR 4.6%, supported by advanced medical facilities.
• United Kingdom: USD 21.33 million by 2034 from USD 12.22 million in 2025, CAGR 4.6%, driven by critical care expansions.
• Italy: USD 13.22 million by 2034 from USD 7.44 million in 2025, CAGR 4.5%, fueled by respiratory care units.
• Spain: USD 8.11 million by 2034 from USD 4.33 million in 2025, CAGR 4.5%, supported by ECMO hospital adoption.

ASIA-PACIFIC

Asia-Pacific is a rapidly expanding ECMO region, now contributing roughly 20–30% of registry-reported runs in many datasets and accounting for accelerated program growth in countries such as China, Japan, South Korea, Australia and India; some national programs report dozens to hundreds of runs annually at major centers. Asia-Pacific adoption includes a mix of hospital-owned consoles and leased transport units, with consumable procurement volumes growing in parallel to run counts—centers in large metropolitan areas may consume hundreds to thousands of oxygenator kits annually as their programs scale from 10–50 runs to 50–200 runs.

Asia is projected to reach USD 90.33 million by 2034 from USD 57.33 million in 2025, at a CAGR of 4.6%, driven by growing ICU capacity and increasing prevalence of respiratory and cardiovascular diseases.

Asia - Major Dominant Countries

• Japan: USD 31.33 million by 2034 from USD 19.22 million in 2025, CAGR 4.6%, fueled by high ECMO adoption in hospitals.
• China: USD 28.44 million by 2034 from USD 17.22 million in 2025, CAGR 4.6%, supported by expanding critical care infrastructure.
• India: USD 15.33 million by 2034 from USD 9.22 million in 2025, CAGR 4.6%, driven by rising ICU adoption.
• South Korea: USD 9.22 million by 2034 from USD 5.33 million in 2025, CAGR 4.6%, fueled by advanced hospital ECMO usage.
• Rest of Asia: USD 6.11 million by 2034 from USD 3.33 million in 2025, CAGR 4.55%, supported by regional critical care expansion.

MIDDLE EAST & AFRICA

Middle East & Africa presently represent a smaller slice—often <5–10%—of global ECMO runs but are notable for high-investment tertiary centers and emerging regional referral hubs; leading centers in the Gulf and South Africa run 10–50+ ECMO cases annually and maintain contingency transport arrangements. Consumable logistics in MEA can require buffer inventories equal to 4–12 weeks of usage due to longer import lead times and customs timelines, and centers often partner with regional distributors to manage supply chain continuity.

The Middle East & Africa market is expected to grow from USD 27.33 million in 2025 to USD 36.33 million by 2034, at a CAGR of 3.8%, driven by increasing critical care infrastructure and ECMO adoption.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia: USD 11.33 million by 2034 from USD 7.22 million in 2025, CAGR 4.0%, fueled by hospital ECMO adoption.
• United Arab Emirates: USD 8.11 million by 2034 from USD 5.22 million in 2025, CAGR 3.8%, supported by private and public hospital growth.
• South Africa: USD 5.22 million by 2034 from USD 3.11 million in 2025, CAGR 3.7%, driven by critical care expansion.
• Egypt: USD 4.11 million by 2034 from USD 2.33 million in 2025, CAGR 3.6%, fueled by rising ICU facilities.
• Rest of MEA: USD 7.66 million by 2034 from USD 4.44 million in 2025, CAGR 3.8%, supported by regional ECMO adoption.

List of Top ECMO Devices Companies

• Microport Scientific
• Maquet Holding
• Medtronic
• Terumo Cardiovascular
• Medos
• Nipro Medical
• Sorin

Getinge / MAQUET (Maquet Holding): Multiple industry analyses report Getinge/MAQUET with approximately ~20% market share in ECMO systems and disposables in recent competitive mappings, supported by a wide product portfolio covering consoles, oxygenators and circuit kits and distribution across >50 countries.

Medtronic: Medtronic appears among the top suppliers in ~10–18% of procurement and market analyses, with its ECMO-relevant offerings (pumps, oxygenators, accessories) used in numerous tertiary centers and forming a key competitor in consumable and console segments.

Investment Analysis and Opportunities

Investment in the ECMO Devices Market centers on councilable capital spend for consoles, recurring consumable supply relationships, and training/service bundles; average hospital ECMO program procurement often includes 1–6 consoles and recurring consumable orders sized to expected runs (e.g., 50–200+ kits yearly at mid-to-high-volume centers). Investment opportunities exist in mobile transport consoles as 20–35% of new program procurements specify portability to support ECMO retrievals, and in consumables where each ECMO run consumes 1 oxygenator and circuit kit yielding predictable recurring purchasing volumes tied to registry run counts (e.g., 12,963 adult runs imply at least 12,963 adult kits). Suppliers that offer integrated training programs—typical centers require 16–40 hours annual training per clinician—can increase program adoption rates and capture service revenue equal to 10–30% of annual device spend in many contractual models.

New Product Development

Innovation in ECMO Devices Market focuses on compact consoles, integrated monitoring, hemocompatible oxygenators, and single-use tubing kits. Recent device roadmaps show portable consoles shrinking weight from 50–100+ kg to <25–35 kg in some models, enabling ambulance and aircraft transport missions and increasing deployable retrieval units per system by 1–3 per provider. Oxygenator surface chemistry advances aim to reduce platelet activation and hemolysis, extending safe oxygenator lifespans from typical 6–10 days to validated 8–14 day support in selected cohorts, which reduces disposable turnover rates per prolonged run. Integrated pump and sensor designs now report flow accuracies within ±5% across 0.5–7 L/min ranges, helping clinicians meet target flows for adult support measured in 3–6 L/min.

Five Recent Developments

• ELSO registry reporting showed 12,963 adult ECMO runs in 2022, confirming adult dominance in annual volumes.
• Median adult ECMO runs per center rose from 4 (2009) to 15 (recent), demonstrating higher per-center utilization.
• Portable/transport-capable ECMO consoles now figure in 20–35% of new procurements in large system tenders.
• Leading supplier competitive mappings report Getinge/MAQUET with about ~20% market share and Medtronic in the ~10–18% band among major ECMO suppliers.
• High-volume acquisition patterns show hospitals ordering 1–6 consoles per program and maintaining consumable stocks covering 2–8 weeks of projected runs.

Report Coverage of ECMO Devices Market

This ECMO Devices Market Research Report covers device segmentation (VV ECMO 55–65%, VA ECMO 30–40%, AV ECMO <10%), end-user segmentation (hospitals 60–80%, clinics/diagnostic centers <10%, ambulatory/surgical centers <5%) and regional distribution (North America 30–40%, Europe 20–30%, Asia-Pacific 20–30%, MEA <10%). It quantifies utilization with ELSO-reported runs (adult 12,963, pediatric 2,457, neonatal 1,383 in 2022), program volumes (median adult runs per center moved from 4 to 15 since 2009), and operational metrics (typical cannulation targets 30–90 minutes and median VV run durations of 5–14 days). The scope includes capital vs. consumable purchasing splits—consoles and capital equipment versus recurring oxygenator and circuit-kit demand where 1 kit is consumed per run—and service models (training commitments averaging 16–40 hours per clinician annually and program support bundles covering 12–36 month service contracts). Coverage also maps supplier presence and competitive concentration, where leading suppliers hold single-digit to low-twenties percent shares, helping procurement teams evaluate console, consumable and training offers for ECMO Devices Market Forecasting and ECMO Devices Market Opportunities.

ECMO Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 296.38 Million in 2026
Market Size Value By	USD 445.06 Million by 2035
Growth Rate	CAGR of 4.62% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : VV ECMO VA ECMO AV ECMO By Application : Hospitals Diagnostic Centre Clinics Ambulatory Surgical Centre
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample